Hence, the data highlight the expression of BTLA in oral cancer and motivate clinical trials of anti-BTLA therapy—preferentially as a concept of a simultaneous therapeutic targeting of multiple inhibitory signalling pathways like PD1, CD96 and BTLA—in oral cancer. This evidence concerns the gene CD96 and lip and oral cavity carcinoma.